Cabozantinib S-Malate
The s-malate salt form of cabozantinib, the standard formulation used for treating advanced kidney cancer, liver cancer, and thyroid cancer. By blocking multiple kinase receptors, it disrupts tumor blood supply and cancer cell survival pathways. Salt form selection improves the drug's oral bioavailability.
分子量
635.6000 g/mol
TPSA
194.00 Ų
治疗领域
作用机制
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
二维结构
Cite this structure
Embed this structure
SMILES
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
InChI
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
Molecular Formula
C32H30FN3O10
HBD / HBA
5 / 12
可旋转键数
11
重原子数
46
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
The s-malate salt form of cabozantinib, the standard formulation used for treating advanced kidney cancer, liver cancer, and thyroid cancer. By blocking multiple kinase receptors, it disrupts tumor blood supply and cancer cell survival pathways. Salt form selection improves the drug's oral bioavailability.
Inhibits vascular endothelial growth factor (VEGF) signaling, blocking angiogenesis (new blood vessel formation) that tumors require for growth and metastasis.
Yes, Cabozantinib S-Malate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103868. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25102846. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cabozantinib-s-malate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cabozantinib-s-malate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cabozantinib-s-malate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cabozantinib-s-malate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cabozantinib-s-malate"></drugfyi-drug>